On Monday, Neurocrine Biosciences, Inc. (NASDAQ:NBIX)’s shares declined -8.92% to $39.50.
Neurocrine Biosciences, Inc. (NBIX) declared that the Company will report its first quarter 2015 results before the Nasdaq market opens on Thursday, April 30, 2015. Neurocrine will then host a live conference call and webcast to talk about its financial results and provide a Company update Thursday morning, April 30, 2015 at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time).
Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States.
Advaxis, Inc. (NASDAQ:ADXS)’s shares dropped -8.83% to $21.28.
ADXS31-164 is a novel Lm-LLO immunotherapy developed by Advaxis, Inc. (ADXS) to target HER2 receptor expressing cancers. In March 2014, Aratana licensed ADXS31-164 from Advaxis for the treatment of canine osteosarcoma and other cancers, adding the drug product to its pipeline of cancer therapeutics as AT-014.
On Monday, April 20, Nicola J. Mason, BVetMed, Ph.D., DACVIM, Assistant Professor of Medicine, University of Pennsylvania’s School of Veterinary Medicine, presented preliminary data from an ongoing Phase 1 clinical study of 10 companion dogs with osteosarcoma (Poster Board #7; Abstract #LB-113). The data suggests that ADXS31-164 in combination with palliative radiation delayed tumor progression and prolonged overall survival in pet dogs with spontaneous osteosarcoma that were not candidates for primary tumor removal (amputation). Repeat doses of ADXS-HER2 were well tolerated with no systemic or cardiac toxicity. Additionally, the combination treatment was found to maintain or improve limb function and quality of life over the study period. Five of the treated dogs remain alive, with a median survival, to date, of all 10 study dogs stated at 285 days, which compares favorably to historical median survival time of 136 days in dogs treated with palliative radiation only.
Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies in the United States.
At the end of Monday’s trade, Viggle Inc (NASDAQ:VGGL)‘s shares dipped -8.63% to $2.33.
Viggle Inc (VGGL) the entertainment marketing and rewards platform, has planned a conference call on Monday, May 11, 2015 at 9:00 A.M. Eastern Time (ET) to review results for the fiscal 2015 third quarter ended March 31, 2015.
Viggle Inc. operates as a mobile and Web-based entertainment marketing platform for media companies, brands, and consumers in the United States. It guides users towards various forms of media consumption with television enhancement, music discovery, entertainment content publishing, and distributed viewing reminders.
Merrimack Pharmaceuticals Inc (NASDAQ:MACK), ended its Monday’s trading session with -8.53% loss, and closed at $12.27.
Merrimack Pharmaceuticals Inc (MACK) and Baxter International Inc. (BAX) recently jointly declared that Merrimack has accomplished the rolling submission of the New Drug Application (NDA) for MM-398 (irinotecan liposome injection), also known as “nal-IRI,” to the U.S. Food and Drug Administration (FDA). Merrimack is seeking U.S. marketing approval of MM-398 for the treatment of patients with metastatic adenocarcinoma of the pancreas who have been formerly treated with gemcitabine-based therapy. The companies also declared that Merrimack has requested precedingity review of the MM-398 NDA by the FDA.
Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and preparing to commercialize medicines paired with companion diagnostics for the treatment of cancer primarily in the United States.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
